PCF Award Recipient Steven Balk Chairs Session on Advances in Androgen Receptor Discovery
April 2, 2012 -- Prostate Cancer Foundation Challenge Award recipient, Steven P. Balk at Beth Israel Deaconess Medical Center in Boston, MA chaired a session focused on recent advances made in targeting androgen receptors for prostate cancer prevention and therapy. Session speakers, including PCF-funded researcher Peter S. Nelson at Fred Hutchinson Cancer Research Center in Seattle, WA, and Scientific Advisory member for the PCF-supported Coalition to Cure Prostate Cancer Marianne Sadar at the BC Cancer Foundation in Vancouver, BC, Canada discussed the precise functions of androgen receptors in prostate cancer and how they may be altered during prostate cancer progression.
Since the Food and Drug Administration’s (FDA) approval of abiraterone, it has become even clearer that increased intratumoral androgen synthesis contributes to the restoration of androgen receptor activity in hormone refractory metastatic prostate cancer. Speakers also addressed the current challenges of understanding the basis of resistance to abiraterone and related drugs. Looking ahead, panelists outlined new androgen receptor antagonists that appear to be efficacious in metastatic disease and other signal transduction pathways that may contribute to prostate cancer development or progression. Additional speakers included and Nancy L. Weigel, Baylor College of Medicine, Houston, TX.